Vivo Capital LLC lowered its position in Genocea Biosciences Inc (NASDAQ:GNCA) by 92.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 626,401 shares of the biotechnology company’s stock after selling 7,184,805 shares during the period. Vivo Capital LLC owned 2.40% of Genocea Biosciences worth $2,455,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in GNCA. Wedbush Securities Inc. bought a new position in shares of Genocea Biosciences in the 2nd quarter worth approximately $43,000. Wells Fargo & Company MN increased its position in Genocea Biosciences by 271.9% during the 2nd quarter. Wells Fargo & Company MN now owns 33,631 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 24,587 shares in the last quarter. Fosun International Ltd increased its position in Genocea Biosciences by 41.5% during the 1st quarter. Fosun International Ltd now owns 571,028 shares of the biotechnology company’s stock valued at $345,000 after buying an additional 167,350 shares in the last quarter. Monashee Investment Management LLC bought a new position in Genocea Biosciences during the 2nd quarter valued at approximately $392,000. Finally, FNY Investment Advisers LLC bought a new position in Genocea Biosciences during the 2nd quarter valued at approximately $526,000. 55.95% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently weighed in on GNCA. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective (down previously from $42.00) on shares of Genocea Biosciences in a research report on Thursday, July 25th. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Wednesday, July 3rd. ValuEngine raised Genocea Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Stifel Nicolaus began coverage on Genocea Biosciences in a research report on Monday, July 8th. They set a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Genocea Biosciences has an average rating of “Buy” and an average price target of $18.25.

In other Genocea Biosciences news, major shareholder Peter W. Sonsini bought 2,857,142 shares of Genocea Biosciences stock in a transaction on Monday, June 24th. The stock was acquired at an average price of $3.50 per share, with a total value of $9,999,997.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. 2.33% of the stock is currently owned by company insiders.

Shares of Genocea Biosciences stock traded up $0.11 on Friday, reaching $3.55. The company’s stock had a trading volume of 5,796 shares, compared to its average volume of 100,908. The company has a market capitalization of $89.96 million, a price-to-earnings ratio of -0.96 and a beta of 2.53. The firm’s fifty day simple moving average is $3.25 and its two-hundred day simple moving average is $2.51. Genocea Biosciences Inc has a 52 week low of $2.24 and a 52 week high of $11.28. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.45.

Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Thursday, July 25th. The biotechnology company reported ($0.67) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.02). As a group, research analysts predict that Genocea Biosciences Inc will post -2.13 EPS for the current year.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Article: How are dividend achievers different from dividend aristocrats?

Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences Inc (NASDAQ:GNCA).

Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.